

Outcomes Following Surgical Repair of Sinus Venosus Atrial Septal Defects: A Systematic Review

Ryaan El-Andari^{a*}, MD, Muhammad Moolla^{b*}, MD, Kevin John^c, MBBS, Ashley Slingerland^d, BSc, Sandra Campbell^e, MLS, Jeevan Nagendran^a, MD, Anoop Mathew^b, MBBS.

***Co-first authors**

^aDivision of Cardiac Surgery, Department of Surgery, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada.

^bDivision of Cardiology, Department of Medicine, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada.

^cMBBS. Division of Internal Medicine, Department of Medicine, Tufts University, Medford, Massachusetts, USA.

^dFaculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.

^eUniversity of Alberta Library, Edmonton, Alberta, Canada.

Running Title: Sinus Venosus ASD

Word count: 3771 words

Grant support: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Disclosures: Sandra Campbell, Ashley Slingerland, and Drs. El-Andari, Moolla, John, Nagendran, Mathew report no relationships with industry that could be construed as a conflict of interest

Address for correspondence:

Dr. Anoop Mathew

Mazankowski Alberta Heart Institute, University of Alberta Hospital,
11220 83 Avenue NW, Edmonton, AB, Canada T6G 2B7

P: 587-990-8759

F: 780-407-4547

E: anoop.mathew@ualberta.ca

Twitter: @anoop_alberta

Abstract

Background

Sinus venosus atrial septal defect (SVASD) is a rare congenital cardiac anomaly comprising 5-10% of all atrial septal defects. Although surgical closure is the standard treatment, data on outcomes have been confined to small cohorts.

Methods

We conducted a systematic review and meta-analysis of studies reporting the outcomes of surgical repair of SVASD. The primary outcome was mortality. Secondary outcomes encompassed atrial fibrillation, sinus node dysfunction, pacemaker insertion, cerebrovascular accident (CVA), reoperation, residual septal defect, superior vena cava (SVC) obstruction, and reimplemented pulmonary vein obstruction, occurring after surgical repair of SVASD. Pooled incidences of outcomes were calculated using a random effects model.

Results

Forty studies involving 1,292 patients who underwent SVASD repair were included. The majority were male (59.4%), with 92.9% presenting with associated pulmonary anomalous venous connection. The weighted mean ages were 18.6 ± 12.5 years, and the overall weighted mean follow-up period was 8.6 ± 10.4 years. In-hospital mortality rate was 0.24%, with a 30-day mortality of 0.56% reported in 720 patients. Incidences of atrial fibrillation, sinus node dysfunction, pacemaker insertion, and CVA over the long-term follow-up were 2% (1-3%), 4% (2-6%), 2% (1-2%), respectively. Reoperation, residual septal defect, SVC obstruction, and reimplemented pulmonary vein obstruction occurred in 1% (0-2%), 2% (2-2%), 1% (1-1%), and 2% (2-2%) surgeries, respectively.

Conclusions

This is the first comprehensive analysis of outcomes following surgical repair of SVASD. The findings affirm the safety and effectiveness of surgery, establishing a reference point for evaluating emerging transcatheter therapies. Comparable safety and efficacy profiles to surgical repair are essential for widespread adoption of transcatheter treatments.

Keywords: sinus venosus atrial septal defect, surgery

Abbreviations: Atrial septal defect = ASD, sinus venosus atrial septal defect = SVASD, superior vena cava = SVC, cerebrovascular accident = CVA, persistent left sided superior vena cava = pLSVC, partial anomalous pulmonary venous connection = PAPVC.

Introduction

The management of sinus venosus atrial septal defect (SVASD), a rare congenital cardiac anomaly caused by abnormal septation of the embryologic sinus venosus, has witnessed rapid evolution with the introduction of innovative transcatheter techniques¹⁻⁵. Nevertheless, surgical repair has maintained its position as the established standard of care.

Several approaches to surgical repair with sternotomy, mini-sternotomy, thoracotomy, and robotic surgery, have been described. Of these, standard patch repairs and the Warden technique are the most utilized⁶⁻¹⁰. However, due to the rarity of this anomaly, the available outcome data for patients undergoing SVASD repair is primarily derived from limited single-center experiences with small patient cohorts. This scarcity of outcome data presents challenges in assessing the safety and effectiveness of novel therapies when comparing them to the established surgical benchmark. Motivated by this gap in knowledge, we undertook a systematic review aiming to establish the existing outcome standards for the surgical repair of SVASDs.

Methods

Search criteria

We searched PROSPERO, MEDLINE, EMBASE, and Cochrane Library databases to identify studies. Search terms included “sinus venosus”, “ASD”, and “atrial septal defect”. We searched the listed databases from 1980 to the present day. The search was restricted to humans and English language studies.

Study selection

We included randomized trials, prospective and retrospective case series, as well as cohort studies that reported outcomes of patients with SVASD. Inclusion criteria included studies reporting outcome data after surgical repair of SVASD. Studies not reporting patient outcomes, and case reports with two or less patients were excluded.

All abstracts and titles were screened for inclusion by three independent reviewers (RE, KJ, and MM). Two other reviewers (AS and RE) screened excluded studies to ensure no studies were incorrectly excluded. Full-text articles were assessed against inclusion and exclusion criteria by three independent reviewers (RE, KJ, and MM), with discrepancies resolved by a fourth reviewer (AM).

Data extraction

Four reviewers (RE, AS, KJ, and MM) independently extracted pertinent data from full-text articles, and discrepancies in data extraction were resolved by consensus. We collected qualitative data on coexistent cardiac lesions, SVASD type, surgical approach, and repair technique. The primary outcome was mortality. Secondary outcomes included: stroke, atrial fibrillation, sinus node dysfunction, pacemaker insertion, reoperation, superior vena cava (SVC) obstruction, reimplanted pulmonary vein obstruction, and residual atrial septal defect.

Quality evaluation

The Newcastle-Ottawa Quality Assessment Form for Cohort Studies was used to evaluate included studies for risk of bias¹¹. Each study was judged on eight items, across three groups: selection and comparability of the study groups, as well as outcome assessment. Stars were awarded for each quality item, and the highest quality studies were awarded up to nine stars.

Risk of bias was assessed by two reviewers (KJ and MM) with disputes resolved by a third reviewer (AM). We categorized risk of bias as high (score of 0-3), moderate (4-6), or low (7-9).

Statistical analysis

We presented categorical variables as frequencies and percentages, while continuous data were expressed as mean \pm standard deviation (SD) or median \pm interquartile range (IQR) where applicable. We used Cochrane Review Manager (RevMan) 5.4.1 software to analyze the data¹². Given the expected heterogeneity across studies, we utilized a random-effects model to estimate pooled incidence with a 95% confidence interval (CI). Estimates of pooled outcomes were expressed as a percentage of 100 patients who underwent SVASD repair and a standard correction factor of 0.5 was applied when event rates were 0 in an individual study¹². In most cohorts, the incidence of mortality was 0%, rendering the pooling of such data clinically meaningless. Therefore, we reported this estimate as “not applicable”. Inconsistency index (I^2) statistic was calculated to determine the proportion of the variance in the estimated effect attributed to study heterogeneity. The amount of heterogeneity was quantified by the I^2 statistic as low (25%), moderate (50%), or high (75%)¹³.

Results

Study selection

Database search yielded 841 studies after removal of duplicates (Figure 1). Five of these studies were obtained from study reference lists. A total of 141 full-text articles were retained after the screening of titles and abstracts using the exclusion criteria. Full-text articles were reviewed and 40 studies meeting the inclusion criteria were included for qualitative and

quantitative synthesis (Table 1). According to the Newcastle-Ottawa Scale, no study had a low risk of bias, 39 had moderate risk, and 1 had high risk of bias. (Supplemental Table 1)

Study characteristics

Across 40 studies, 1292 patients underwent SVASD repair. Most patients (92.9%) had associated PAPVC. A persistent left sided superior vena cava (pLSVC) was the second most common associated lesion found in 79 (20.8%) patients across 7 studies. Majority were males (59.4%) and the weighted mean age at repair was 18.6 ± 12.5 years. Weighted mean follow-up duration was 8.6 ± 10.4 years. A total of 594 patients across 12 studies had a superior type of SVASD, while 60 patients in 4 studies had an inferior type of SVASD (Table 1).

Operative data

Various surgical approaches were documented in multiple studies, with sternotomy emerging as the most common technique, employed in a total of 699 patients across 18 studies (Table 1). A subset of studies utilized a mini-sternotomy approach, incorporating both upper and lower sternal access, which was applied to 55 patients across 4 studies. A minimally invasive approach was adopted in 9 studies, encompassing a cohort of 209 patients.

The primary surgical repair approach most frequently used was the single patch technique, across 22 studies involving 676 patients (Table 1). Alternative repair methods included the two-patch repair, performed on 252 patients across 14 studies, and the Warden repair, employed in 8 studies involving 160 patients. Also, a modified Warden repair was reported in 24 patients in a separate study, while a double barrel repair was used in 50 patients in yet another study. Other techniques reported included repair utilizing a flap of the atrial septum reported in a small study (5 patients), as well as primary repair through direct suture closure (5

patients across 2 studies). As for ancillary procedures, secundum ASD repair emerged as the most prevalent, with 29 cases reported across 3 studies.

Outcomes

There were 3 deaths in the early postoperative period, resulting in an in-hospital mortality rate of 0.24% (Table 2). Follow-up data at 30 days available for 720 patients across 21 studies with 4 deaths overall, resulting in a 30-day mortality of 0.56% (Figure 2). Long-term mortality data, including deaths not related to cardiac or operative causes were available in a few studies^{6,14-18} (Table 2). Calculation of pooled incidences for mortality was not statistically feasible, given that a standard correction factor of 0.5 would overestimate the mortality rate. Descriptive data was available for 3 of the 4 deaths in the first 30 days. Chu et al. report the death of a 64-year-old man with diabetes, coronary artery disease, and renal failure who underwent repair of SVASD and PAPVC¹⁹. He passed away postoperatively after developing bowel ischemia. Jost et al. report the death of a 76-year-old female with preoperative NYHA class IV heart failure who underwent patch closure of SVASD, suture closure of a patent foramen ovale, and tricuspid valve replacement⁶. She died on postoperative day 6 from right heart failure. Russell et al. describe the death of a pediatric patient who underwent SVASD repair via a median sternotomy approach and single pericardial patch repair²⁰. Initially, the repair was uncomplicated, and the patient was discharged on postoperative day 8, however, at day 23 the patient died from pericardial tamponade secondary to an undiagnosed pericardial effusion.

Throughout a weighted mean follow-up period of 6.5 years, the pooled incidence of atrial fibrillation was found to be 2% (1-3%) (Table 3). Likewise, over a weighted mean follow-up period of 6.4 years, the pooled incidence of sinus node dysfunction was 4% (2-6%), whereas the incidence of pacemaker insertion over a longer follow-up duration of 8.6 years was 2% (1-2%).

Given the inherent clinical variability associated with a diagnosis of sinus node dysfunction, the level of heterogeneity was deemed moderate to high at 74%. In contrast, the level of heterogeneity for pacemaker insertion related outcomes was low. Finally, based on findings from the 5 studies reporting on CVAs, the combined incidence was 1% (0-3%) over a weighted mean follow-up period of 12.3 years.

Operative complications

Surgery-specific postoperative complications of interest included reoperation, residual septal defect, SVC obstruction, and reimplanted pulmonary vein obstruction.

In 20 studies with a total of 807 patients and a weighted mean follow-up period of 9.5 years, only 11 cases necessitated reoperation, resulting in a pooled incidence rate of 1% (0-1%). Reoperations primarily occurred in children and during the early postoperative phase. The reasons for reoperation varied across studies, including excess bleeding from the thymic bed or sternal wires, misdiagnosed residual shunts, SVC obstruction and thrombosis, bleeding complications, and symptomatic pulmonary vein obstruction. These cases were managed through re-exploration, augmentation with additional patches, or revision surgery. Further details on re-operative data are included in the supplemental index (Supplemental Results).

Out of a total of 747 patients observed for 9.3 years, only 10 individuals were identified to have a persistent atrial septal defect. The pooled incidence was calculated to be 2% (2-2%), and the level of heterogeneity among these studies was high. Among these cases, 5 patients had residual defects resulting from undetected inferior SVASDs, with four of them requiring reoperation²¹. The remaining five patients had residual shunts without any significant hemodynamic consequence^{20,22}.

The overall rate of SVC obstruction was low with only 14 cases among 795 patients. The pooled incidence was 1% with study heterogeneity was high at 100% across the 18 studies. Among the 14 cases, 5 were deemed hemodynamically significant lesions. The type of repair in these instances was inconsistently reported (Table 1). Among the five significant cases, one patient refused corrective surgery and one patient had not had intervention at the time of publication^{17,18}. The remaining three patients were successfully managed, one with surgery, another with balloon angioplasty, and the last with stenting²³⁻²⁵.

The rate of SVC obstruction was relatively low, among 795 patients, with only 14 cases identified. This resulted in a pooled incidence rate of 1%, with high study heterogeneity. The specific type of repair for these cases was inconsistently reported^{17,18,23-25}. However, only 3 patients required interventions: one underwent surgery, another received balloon angioplasty, and the last patient underwent stenting²³⁻²⁵.

Reimplanted pulmonary vein obstruction occurred in 11 out of 784 patients with a pooled incidence of 2% (2-2%) and study heterogeneity was high. Iyer et al. reported 9 cases of hemodynamically significant right superior pulmonary vein obstruction all exclusively occurring in the group with single patch repair, and they compared this to their group of patients who underwent double patch repair, where there were no cases¹⁷. None of these patients required reintervention. The final two cases of pulmonary vein obstruction were described by Shahriari et al. in which one of whom needed revision surgery 5 years after their Warden procedure, and the other who only had mild obstruction after single patch repair that did not require correction²⁶.

Discussion

SVASD is a rare congenital cardiac anomaly accounting for 5-10% of all ASDs^{6,27}. It results from faulty embryological resorption of the sinus venosus at the cavo-atrial junction. This typically results in complex defects at the confluence of the superior vena cava, right sided pulmonary veins, and superior aspect of the atria. Rarely, these defects can involve the inferior vena cava - atrial septal confluence. SVASDs are commonly associated with other congenital cardiac anomalies, the most common being anomalous pulmonary venous return involving the right upper pulmonary vein^{6,27}.

While surgical intervention continues to be the established approach for repairing SVASD, transcatheter repair is rapidly emerging as an alternative treatment strategy and is progressively gaining acceptance¹⁻⁵. However, a head-to-head comparison between transcatheter repair and surgery has not been undertaken. Moreover, there have not been large multicenter studies defining the long-term outcomes of surgical repair of SVASD. Consequently, an unmet need exists in establishing the surgical standard against which novel transcatheter therapies can be effectively assessed. This systematic review represents the first comprehensive review of the literature on this topic.

Since SVASD is rare, surgical repair is often done in specialized centers performing high volumes of congenital heart disease surgeries^{6,27}. The result is the publication of multiple single center studies with relatively small cohorts of patients undergoing SVASD repair. Several different surgical approaches and techniques have been described. The surgical approaches range from standard median sternotomy, anterior and posterior thoracotomy, endoscopic, and minimally invasive robotic approaches^{6,8,19,28-33}. Commonly described surgical techniques include standard patch repairs, Warden technique, and caval flap repair^{6-8,10,16,34}. Despite the heterogeneity in surgical approaches and repair techniques, the overall short-term outcomes have

been excellent. We report an in-hospital mortality rate of 0.24% and 30-day mortality rate of 0.56% in patients undergoing surgical SVASD repair. The success of surgical SVASD repair is not limited to measures of mortality. At a mean follow-up of just over 6 years, the pooled incidence of atrial fibrillation was 2% and sinus node dysfunction was 4%. 6.5 years. The incidence of pacemaker insertion was 2% over 8.6 years. Over the long-term the 2% of patients had residual ASD, whereas the rates of SVC stenosis and need for reoperation were extremely low at 1%.

The landscape of SVASD repairs has undergone rapid evolution. Recent publications have brought to light the favorable outcomes achieved through minimally invasive techniques, and in some cases, even robotic-assisted approaches to SVASD repair^{29,30}. Furthermore, as delineated earlier, the adoption of transcatheter repair methods has gained widespread traction. From an anatomical standpoint, a substantial proportion, up to 75%, of individuals with SVC-type SVASDs could be potential candidates for transcatheter repair⁴. The key anatomical determinant that influences the feasibility of trans-catheter closure of the interatrial communication and redirection of pulmonary venous flow is the direct continuity between the posterior wall of the anomalous pulmonary vein and the left atrium. The principal advantage of trans-catheter closure resides in the brief duration of hospitalization and the low incidence of sinus node dysfunction associated with the procedure. However, patients undergoing transcatheter repair do face potential procedural and long-term risks. These risks remain rare but include cardiac perforation, hemopericardium, stent embolization, and residual interatrial shunts⁴.

Considering the exceedingly low mortality risk associated with both surgical and transcatheter repair of SVASD, designing sufficiently powered studies to effectively compare

these treatment approaches poses a challenge. Nevertheless, in studies aiming to evaluate these therapeutic strategies, it is imperative to define appropriate clinical endpoints. These endpoints should encompass commonly encountered postprocedural complications, such as atrial fibrillation, sinus node dysfunction, pacemaker implantation, as well as instances of superior vena cava and pulmonary vein obstruction.

Most reported cohorts of patients who undergo surgical repair have not undergone systematic follow-up accompanied by pre-defined cross-sectional imaging. Consequently, this could lead to an underestimation of complications, including the potentially asymptomatic instances of superior vena cava and pulmonary vein obstruction, particularly when occlusion manifests in an insidious manner.

Limitations

While the results of this review provide a comprehensive overview of the literature published on surgical repairs of SVASD, this manuscript has several limitations. First, many of the pooled analyses carried a high rate of heterogeneity limiting our ability to make inferences based on that data. Second, patient specific predictors of outcomes following surgical repair have not been adequately reported. Reported adverse events were concentrated in a few centers suggesting that outcomes may be underreported in remaining studies. Establishing a standardized framework for documenting preoperative and postoperative variables would enable more rigorous analyses and facilitate the judicious selection of patients suited for surgical repair in comparison to transcatheter alternatives.

Conclusions

The landscape of surgical management for SVASD has undergone rapid evolution, yielding a diverse array of surgical approaches and techniques. Multiple centers have achieved excellent outcomes, showcasing both low operative mortality rates and favorable long-term results. As transcatheter-based methods for SVASD repair continue to emerge, they must meet or exceed the established surgical benchmarks, especially in terms of the long term risk profile.

Clinical Perspectives

Competency in medical knowledge

SVASD is a rare congenital cardiac defect that has historically been treated with surgical repair. Due to the rarity of the defect, data on the outcomes after surgery have not been systematically reviewed. Based on the currently available literature, surgical repair of SVASD carries low operative risk with favorable long-term results.

Translational outlook

Nearly 75% of SVASDs may be amenable to transcatheter repair. Further studies are necessary to ensure the outcomes of transcatheter repair are comparable to the excellent outcomes of surgery.

Acknowledgments

None

References

1. Meier B, Gloekler S, Dénéreaz D, Moschovitis A. Percutaneous repair of sinus venosus defect with anomalous pulmonary venous return. *Eur Heart J*. 2014;35(20):1352. doi:10.1093/eurheartj/ehu088
2. Riahi M, Velasco Forte MN, Byrne N, et al. Early experience of transcatheter correction of superior sinus venosus atrial septal defect with partial anomalous pulmonary venous drainage. *EuroIntervention J Eur Collab with Work Gr Interv Cardiol Eur Soc Cardiol*. 2018;14(8):868-876. doi:10.4244/EIJ-D-18-00304
3. Morgan GJ, Zablah J. A new FDA approved stent for congenital heart disease: First-in-man experiences with G-ARMORTM. *Catheter Cardiovasc Interv*. 2022;100(7):1261-1266. doi:<https://doi.org/10.1002/ccd.30447>
4. Hansen JH, Duong P, Jivanji SGM, et al. Transcatheter Correction of Superior Sinus Venosus Atrial Septal Defects as an Alternative to Surgical Treatment. *J Am Coll Cardiol*. 2020;75(11):1266-1278. doi:10.1016/j.jacc.2019.12.070
5. Crystal MA, Vincent JA, Gray WA. The wedding cake solution: A percutaneous correction of a form fruste superior sinus venosus atrial septal defect. *Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv*. 2015;86(7):1204-1210. doi:10.1002/ccd.26031
6. Jost CHA, Connolly HM, Danielson GK, et al. Sinus venosus atrial septal defect: Long-term postoperative outcome for 115 patients. *Circulation*. 2005;112(13):1953-1958. doi:10.1161/CIRCULATIONAHA.104.493775

7. Okonta KE, Tamatey M. Is double or single patch for sinus venosus atrial septal defect repair the better option in prevention of postoperative venous obstruction? *Interact Cardiovasc Thorac Surg.* 2012;15(5):900-903. doi:10.1093/icvts/ivs369
8. Ling Y, Gan C, Sandeep B, An Q. Modified Warden procedure for partial anomalous pulmonary venous return to the superior vena cava. *J Card Surg.* 2016;31(10):631-634. doi:10.1111/jocs.12810
9. Nassar M, Agha M, Adel H, Khadragui I. The trans-caval approach for surgical correction of sinus venosus atrial septal defect with partial anomalous pulmonary venous drainage into the superior vena cava: Early experience. *Alexandria J Med.* 2011;47(4):333-336. doi:10.1016/j.ajme.2011.07.017
10. Warden HE, Gustafson RA, Tarnay TJ, Neal WA. An alternative method for repair of partial anomalous pulmonary venous connection to the superior vena cava. *Ann Thorac Surg.* 1984;38(6):601-605. doi:10.1016/s0003-4975(10)62317-x
11. Wells G, Shea B, O'Connell D, et al. Newcastle-Ottawa quality assessment scale cohort studies. *Univ Ottawa.* Published online 2014.
12. Higgins JPT, Thomas J, Chandler J, et al. *Cochrane Handbook for Systematic Reviews of Interventions.* John Wiley & Sons; 2019.
13. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. :557-560.
14. Alkady H, Elnaggar A, Eldegwy M, Nosair A. The Warden procedure for partial anomalous pulmonary venous connection in children: 10 years experience in 65 cases.

- Cardiol Young*. 2020;30(10):1486-1489. doi:10.1017/S1047951120002516
15. Bauer M, Alexi-Meskishvilli V, Nakic Z, et al. The correction of congenital heart defects with less invasive approaches. *Thorac Cardiovasc Surg*. 2000;48(2):67-71.
doi:10.1055/s-2000-9867
 16. Chowdhury UK, Sharma S, Sankhyan LK, et al. Long-Term Outcomes of the Double-Barrel Technique for Superior Sinus Venosus Defect With Partially Anomalous Pulmonary Venous Connection. *World J Pediatr Congenit Hear Surg*. 2020;11(6):733-741. doi:10.1177/2150135120938352
 17. Iyer AP, Somanrema K, Pathak S, Manjunath PY, Pradhan S, Krishnan S. Comparative study of single- and double-patch techniques for sinus venosus atrial septal defect with partial anomalous pulmonary venous connection. *J Thorac Cardiovasc Surg*. 2007;133(3):656-659. doi:10.1016/j.jtcvs.2006.08.076
 18. Jemielity M, Perek B, Paluszkiewicz L, Stachowiak W, Ponizynski A. Results of repair of partial anomalous pulmonary venous connection and sinus venosus atrial septal defect in adults. *J Heart Valve Dis*. 1998;7(4):410-414.
 19. Chu MWA, Losenno KL, Fox SA, et al. Clinical outcomes of minimally invasive endoscopic and conventional sternotomy approaches for atrial septal defect repair. *Can J Surg*. 2014;57(3):75-81. doi:10.1503/cjs.012813
 20. Russell JL, LeBlanc JG, Deagle ML, Potts JE. Outcome following repair of sinus venosus atrial septal defects in children. *Asian Cardiovasc Thorac Ann*. 2002;10(3):231-234.
doi:10.1177/021849230201000309

21. Banka P, Bacha E, Powell AJ, Benavidez OJ, Geva T. Outcomes of inferior sinus venosus defect repair. *J Thorac Cardiovasc Surg*. 2011;142(3):517-522.
doi:10.1016/j.jtcvs.2011.01.031
22. Luciani GB, Viscardi F, Pilati M, Crepaz R, Faggian G, Mazzucco A. Age at repair affects the very long-term outcome of sinus venosus defect. *Ann Thorac Surg*. 2008;86(1):153-159. doi:10.1016/j.athoracsur.2008.03.045
23. Gajjar TP, Hiremath CS, Desai NB. Surgical closure of sinus venosus atrial septal defect using a single patch--transcaval repair technique. *J Card Surg*. 2011;26(4):429-434.
doi:10.1111/j.1540-8191.2011.01270.x
24. Stewart RD, Bailliard F, Kelle AM, Backer CL, Young L, Mavroudis C. Evolving Surgical Strategy for Sinus Venosus Atrial Septal Defect: Effect on Sinus Node Function and Late Venous Obstruction. *Ann Thorac Surg*. 2007;84(5):1651-1655.
doi:10.1016/j.athoracsur.2007.04.130
25. Dave HH, Comber M, Solinger T, Bettex D, Dodge-Khatami A, Prêtre R. Mid-term results of right axillary incision for the repair of a wide range of congenital cardiac defects. *Eur J Cardio-thoracic Surg*. 2009;35(5):864-870. doi:10.1016/j.ejcts.2009.01.022
26. Shahriari A, Rodefeld MD, Turrentine MW, Brown JW. Caval Division Technique for Sinus Venosus Atrial Septal Defect With Partial Anomalous Pulmonary Venous Connection. *Ann Thorac Surg*. 2006;81(1):224-230.
doi:<https://doi.org/10.1016/j.athoracsur.2005.07.015>
27. Schuler PK, Herrey A, Wade A, et al. Pregnancy outcome and management of women with an implantable cardioverter defibrillator: A single centre experience. *Europace*.

- 2012;14(12):1740-1745. doi:10.1093/europace/eus172
28. Yoshimura N, Yamaguchi M, Oshima Y, Oka S, Ootaki Y, Yoshida M. Repair of atrial septal defect through a right posterolateral thoracotomy: A cosmetic approach for female patients. *Ann Thorac Surg.* 2001;72(6):2103-2105. doi:10.1016/S0003-4975(01)03086-7
 29. Vistarini N, Aiello M, Mattiucci G, et al. Port-access minimally invasive surgery for atrial septal defects : A 10-year single-center experience in 166 patients. *J Thorac Cardiovasc Surg.* 2010;139(1):139-145. doi:10.1016/j.jtcvs.2009.07.022
 30. Dang HQ, Le HT, Ngo LTH. Totally endoscopic atrial septal defect repair using transthoracic aortic cannulation in a 10.5-kg-boy. *Int J Surg Case Rep.* 2018;52:103-106. doi:10.1016/j.ijscr.2018.09.054
 31. Lewis CTP, Bethencourt DM, Stephens RL, Cline JL, Tyndal CM. Robotic repair of sinus venosus atrial septal defect with partial anomalous pulmonary venous return and persistent left superior vena cava. *Innov Technol Tech Cardiothorac Vasc Surg.* 2014;9(5):388-390. doi:10.1097/IMI.0000000000000093
 32. Bayya PR, Kottayil BP, Srimurugan B, et al. Transaxillary Approach for Surgical Repair of Simple Congenital Cardiac Lesions: Pitfalls, and Complications. *World J Pediatr Congenit Hear Surg.* 2021;12(3):337-343. doi:10.1177/2150135121989663
 33. Bozso SJ, Evans B, Chu MWA. Minimally invasive periareolar approach to repair sinus venosus atrial septal defect with partial anomalous pulmonary venous connection. *J Card Surg.* 2020;35(7):1653-1656. doi:10.1111/jocs.14591
 34. Nassar M, Fouilloux V, MacÉ L, Kreitmann B, Metras D. Transcaval correction of partial

anomalous pulmonary venous drainage into the superior vena cava. *Ann Thorac Surg*.

2012;93(1):193-196. doi:10.1016/j.athoracsur.2011.09.042




Figure 1. PRISMA Diagram of Search Strategy




Figure 2. Outcomes of Surgical Repair of Sinus Venosus ASD

Table 1. Characteristics of included studies.

Study Name	Study type	SVA SD patients (n)	Duration of Follow-up	Year range for index surgery	Patient age (at time of operation)	Sex (% male)	PAPVC associated (n (%))	Concomitant congenital cardiac lesions (type(n))	SVASD type (type (n (%)))	Repair type (type: n (%)) Type: (Warden 0, Modified Warden 1, Single Patch 2, Two Patch 3, Double Barrel 5, other 6)	Surgical approach (type (n)) (Sternotomy 1, ministernotomy 2, minimally invasive 3, endoscopic 4, robotic 5, other 6)	Concomitant repairs (n (%))
Agarwal 2011	Retrospective Cohort	58	Mean 1.2y (range 1m - 2.8y)	2008-2011	Mean 10.9y	29 (51.7)	58 (100)	pLSVC (26), supracardiac TAPVC (2)	NR	0	1	2 (3.4) supracardiac TAPVC repair

Agrawal 1996	Retrospective Cohort	44	Mean 4±0.7y (range 20d - 10.5y)	1985-1995	Mean 13.3y (range 2 - 41y)	29 (65.9)	44 (100)	Associated left SVC draining into coronary sinus (7)	Superior	3: pericardial patch	1	NR
Ait Ali 2020	Retrospective Cohort	70	Median 4.3y (IQR 1.3–9.4y)	1993-2019	Median 8.8y (IQR 4.3–23.6y)	38 (54.2)	70 (100)	NR	NR	0: 1(1.4) 2: 30 (42.8) 3: 39 (55.7)	1	NR
Alkady 2020	Retrospective Cohort	60	Mean 7.8±1.2y	2010-2020	Mean 3.5±1.4y	31 (52.3)	65 (100)	PDA (11), VSD (7), secundum ASD (5), valvular PS (3), pLSVC (10)	NR	0	1	PDA ligation (11), VSD patch closure (7), ASD patch closure (5), pulmonary valvotomy (3), SVC patch augmentation (18)

Bajwa 2012	Retrospective cohort	32	Mean 5y	2000-2010	Mean 48y (range 26-74y)	14 (44)	32 (100)	PFO (12)	Superior	2 (+ lateral caval flap)	1 (20), 2 (12)	PAPVC repair (32), 21 patients underwent one of the following: PFO closure, CABG, MAZE, TV repair, MV repair, pericardiectomy
Banka 2011	Retrospective Case Series	45	In-hospital	1998-2009	Median 2.7y	26 (58)	NR	NR	Inferior	NR	1 (8), 2 (37)	NR
Baskett 1999	Retrospective Case Series	6	Mean 2.5y (range 2m-4y)	NR	Median 5.5y (range 4-54y)	NR	NR	NR	Superior	2 (modified SVC approach)	1	NR
Bauer 2000	Retrospective Cohort	7	Mean 1.5y (range 3m-2.8y)	1996-1999	Mean 15y (range 2m-42y)	NR	7 (100)	-	NR	NR	2 (2), 3 (5)	PAPVC Repair (7)

Cuypers 2013	Retrospective Cohort	21	Mean 35y (range 30 - 41y)	1968-1980	Mean 7.5±3.5y (range 0-14y)	NR	19 (90)	NR	NR	NR	NR	NR
Dave 2009	Retrospective Cohort	22	Median 4.1y (range 0.4 - 7.1y)	2001-2007	Median 5.1y (range 8m - 16.4y)	NR	11 (50)	NR	NR	2: 5 (22.7), 6: (flap of atrial septum) 5 (22.7), 0: 11(50), 3: 1(4.5)	6: right axillary incision	NR
Deleon 1993	Retrospective Cohort	35	Mean 3± 3y (range 1m - 12y)	1979-1991	Mean 6± 2y (range 7m - 17y)	NR	35 (100)	NR	Superior	2: pericardial baffle	NR	NR
Doll 2002	Retrospective Cohort	26	NR	1996-2002	NR	NR	26 (100)	NR	NR	NR	1 (13), 3 (11.5)	NR
Gajjar 2011	Retrospective Cohort	48	3m	2007-2010	Range 5 - 51y	29 (60.4)	48(100)	PFO/OS ASD 6 (12.5), OS ASD 2 (4.1)	NR	2	1	coexistent PFO/ostium secundum ASD

Glatz 2010	Cross Sectional	30	Mean 10.1±4.7y (range 3.3–20.4y)	1987-2004	Mean 6.4 ± 8.1y (range 1.3–45.7 y)	16 (53.3)	NR	NR	Superior: 24 (80), Inferior: 6 (20)	2: 19 (63.3), 3: 6 (20), 0: 5 (16.6)	NR	NR
Grinda 1996	Retrospective Cohort	12	NR	1984-1994	Mean 24.9 ± 13y (range 12-62y)	0 (0)	12 (100)	NR	NR	2: 6 (50), 3: 6 (50) autologous pericardial patch	3: right anterolateral thoracotomy (RALT)	NR
Horvath 1992	Retrospective Cohort	19	Mean 7.5y (range 2m-20.6y)	1971-1999	Weighted mean 45.9 y	6 (31.6)	NR	isolated SV-ASD (2), SV-ASD + PAPVC (10), SV-ASD +secundum ASD (5), SV-ASD + PAVPC + secundum ASD (2)	NR	2: 12 (63.2) pericardial patch, 3 (15.8) suture closure only, 3 (15.8) both patch + suture closure	NR	secundum ASD (7)

Houck 2018	Retrospective Cohort	18	Median 20y (range 6 - 35y)	NR	Median 37y (range 6–63y)	9 (50)	15 (83)	NR	NR	NR	NR	MV plasty 1 (6), TV plasty 4(22)
Iyer 2007	Retrospective Cohort	40	Mean 1.9y	1999-2005	Mean 15.1y (range 3 – 50y)	NR	40 (100)	NR	NR	2: 18 (45), 3: 19 (48)	NR	NR
Jemielity 1998	Retrospective Cohort	25	Mean 7.8 ± 4y (range 2-16y)	1981-1995	Mean 37.8 ± 13y (range 16-62y)	7 (28)	25 (100)	PAPVC entered SVC (15), PAPVC entered RA (10)	NR	2: pericardial patch	1	NR

Jost 2005	Retrospective Cohort	115	Mean 12y± 8.3y	1972- 1996	Mean 34± 23y (range 1.5- 80y)	54 (47. 0)	112 (97.4)	PLSVC to the coronary sinus (17), secundum ASD closure (10), PFO closure (20), repair of anomalou s pulmonar y venous return (1)	Superior : 109 (95), Inferior: 6 (5)	2: 82 (71), 3: 27 (23), 6: 2 (2) direct suture closure	3: right anterolate ral thoracoto my (RALT)	2 (1.7) CABG, 1 (0.8) tricuspid valve replacemen t, 5 (4.3) tricuspid valve annuloplast y, 1 (0.8) excision of benign pericardial tumor, 1(0.8) cryoablatio n for arrhythmias , 6 (5) neo pulmonary vein constructio n.
Ling 2016	Retrospective cohort	24	Mean 4.6y (range 3m - 8y)	2007- 2015	NR	NR	24(100)	NR	NR	1	1	NR

Luciani 2008	Retrospective Cohort	104	Mean 15 ± 21y	1970-2008	Mean 29 ± 23y	51 (49)	94 (90)	18 (17) ostium secundum, 94 (90) PAPVC	Superior	2: 91 (87), 0: 7 (7), 3: 6 (6)	1	18 (17) secundum ASD closure, 4 (4) CABG, 1 (0.88) MVR/TVR, 1 (0.88) PDA suture
Mishaly 2007	Retrospective Cohort	13	Mean 12.3 ± 10.4m (range 6-45m)	2002-2007	Mean 18 ± 16y	NR	13(100)	NR	NR	2	3	NR
Nassar 2012	Retrospective Cohort	43	Mean 4.4y (range 2m - 9.3y)	2001-2010	Mean 5y (range 8m - 70y)	NR	43 (100)	NR	Superior	2: autologous pericardium	3: cosmetic right thoracotomy	NR
Nicholson 2000	Retrospective Cohort	66	Mean 4.1y (range 1-9y)	1981-1997	Mean 10.2y (range 1.5-65y)	36 (54.5)	0 (0)	4 (6) secundum ASD, 6 (9) LSVC	Superior	2	1	2 (3) CABG, 4 (6) secundum ASD

Panos 2002	Retrospective Cohort	7	Mean 12.1±6.1y (range 0.5-21y)	1980-2001	Mean 26.2 ± 12.0y	NR	7 (100)	NR	NR	3	3: limited right anterolateral thoracotomy (RALT)	NR
Rao 2019	Retrospective Cohort	14	Mean 1.7y	2017-2018	Median 9.5y (range 5-12y)	4 (28.6)	14 (100)	NR	NR	3	3 (RVIAT)	NR
Russel 2002	Retrospective Cohort	44	Median 8.8y (range 15m – 14.7y)	1985-1998	Median 4.2y (range 8m – 13.6y)	30 (68.2)	40 (90.9)	PLSVC 3 (6.8)	NR	2: 41 (93.2), 6: primary repair 3 (6.8)	1	NR
Shahriari 2006	Retrospective Cohort	54	Mean 4.3y (range 1-13y)	1991-2004	Mean 13.4y (range 1.5-58y)	NR	54 (100)	41 (75) low PAPVC 2 of which had scimitar syndrome, 13 (24) high PAPVC	NR	0: 13 (24.1), 2: 41 (75.9),	1	1 (1) concurrent CABG, 12 (22) PAPVC repaired through a superior caval venotomy

Siddiqui 2013	Retrospective Cohort	18	Mean 6.5±9.9m	2006-2011	Mean 9.0 ± 11.7y	NR	NR	NR	NR	2: 6 (33.3), 3: 12 (66.7)	1	
Stewart 2007	Retrospective Cohort	54	Weighted overall mean 2.5y	1990-2006	Mean 9.5 ± 12.6y; median age 4.2y	NR	52 (96)	NR	Superior : 51(94.4) , Inferior: 3 (5.6)	2:24 (44), 3:25 (46), 0:5 (10)	NR	NR
Victor 1995	Retrospective Cohort	30	NR	1982-1995	Range 3.5 - 60y	NR	30 (100)	NR	Superior	2: PTFE patch (20), silk patch (10)	1	NR
Vistarini 2009	Retrospective Cohort	6	Mean 4.3±2.8y	1998-2008	NR	NR	6(100)	NR	NR	NR	3: port-access via a small thoracotomy	NR
Yoshimura 2001	Retrospective cohort	3	5y	1983-2000	NR	0 (0)	NR	NR	NR	2	3: right posterolateral thoracotomy	NR

ASD, atrial septal defect; CABG, coronary artery bypass graft; MV, mitral valve; NR, not reported; OS, ostium secundum; PAPVC, partial anomalous pulmonary venous connection; PFO, patent foramen ovale; PTFE, polytetrafluoroethylene; SVASD, sinus venosus atrial septal defect; SVC, superior vena cava; TAPVC, total anomalous pulmonary venous connection; TV, tricuspid valve.

Table 2. Post operative outcomes.

Study	Follo w-up time (mean (SD/r ange))	Reimplant ed pulmonar y vein obstructio n/stenosis (N, [%])	SVC Obstr uction (N, [%])	Resid ual septal defect/ shunt (N, [%])	Reope ration (N, [%])	Sinus Node Dysfun ction (N, [%])	Atrial fibrill ation N, [%])	Pace make r (N, [%])	Cerebro vascular Accident (N, [%])	Other Postopera tive Outcomes (descripti ve List, N [%])	Oper ative mort ality	Mort ality at 30 days	Morta lity beyon d 30 days
Agar wal 2011	Mean 1.2y (range 1m - 2.8y)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	NR	NR	NR	0 (0)	0 (0)	NR
Agra wal 1996	Mean 4± 0.7y (range 20d - 10.5y)	0 (0) in 25 with TTE	0 (0) in 25 with TTE	0 (0) in 25 with TTE	0 (0)	2 (7.4) junctio nal rhythm	0(0)	1 (3.7)	NR	NR	0 (0)	NR	NR
Ait Ali 2020	Media n 4.3y (IQR 1.3– 9.4y)	NR	NR	NR	NR	15 (21.4) ectopic atrial rhythm	NR	NR	NR	NR	0 (0)	NR	NR

Alkad y 2020	Mean 7.8y ± 1.2y	0 (0)	0 (0)	0 (0)	2 (3.1)	2 (3.1)	NR	NR	NR	5 (7.7) Chest infection	0 (0)	0 (0)	1 (1.7) non- cardia c death
Bajwa 2012	Mean 5y	0 (0)	0 (0)	0 (0)	0 (0)	1 (3.1)	3 (9.4)	NR	NR	NR	0 (0)	NR	NR
Banka 2011	In- hospit al	0 (0)	2 (6.1)	5 (11)	5 (11)	NR	NR	NR	NR	NR	0 (0)	NR	NR
Baske tt 1999	Mean 2.5y (range 2m- 4y)	NR	NR	NR	NR	0 (0)	0 (0)	NR	NR	NR	0 (0)	0 (0)	NR
Bauer 2000	Mean 1.5y (range 3m- 2.8y)	0 (0)	0 (0)	0 (0)	0 (0)	NR	NR	NR	NR	NR	0 (0)	0 (0)	0 (0) at 3m

Bayya 2021	Median 2y (range 1m-3.3y)	NR	NR	NR	NR	NR	NR	NR	NR	NR	0 (0)	0 (0)	NR
Bigdelian 2014	In-hospital	NR	NR	NR	NR	NR	NR	NR	NR	NR	0 (0)	NR	NR
Chowdhury 2020	Mean 8.7y±4.2y	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	NR	NR	0 (0)	0 (0)	0 (0) in patients followed up at 1 year
Chu 2014	1m	NR	NR	NR	NR	NR	NR	NR	0 (0)	NR	1 (8.3)	1 (8.3)	NR
Cingoz 2012	In-hospital	NR	NR	0 (0)	NR	NR	NR	NR	NR	0	0 (0)	NR	NR

Cuyper rs 2013	Mean 35y (range 30- 41y)	NR	NR	NR	0 (0)	NR	NR	NR	1 (4.8)	NR	0 (0)	NR	NR
Dave 2009	Media n 4.1y (0.4 - 7.1y)	NR	1 (4.5)	NR	0 (0)	NR	NR	NR	NR	1(4.5) stenting for SVC stenosis	0 (0)	NR	NR
Deleo n1993	Mean 3± 3y (range 1m- 12y)	NR	NR	NR	NR	NR	NR	NR	NR	NR	0 (0)	0 (0)	NR
Doll 2002	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	0 (0)	NR	NR
Gajja r 2011	3m	0 (0)	1(2)	0 (0)	1(2)	0 (0)	0 (0)	0 (0)	NR	NR	0 (0)	0 (0)	NR

Glatz 2010	Mean 10.1±4.7y (range 3.3–20.4y)	0 (0)	NR	0 (0)	NR	15 (50)	NR	NR	NR	4 (13.3) post cardiomy syndrome	0 (0)	0 (0)	NR
Grinda 1996	NR	NR	NR	0 (0)	NR	NR	NR	NR	NR	NR	0 (0)	NR	NR
Horvath 1992	mean of 7.5y (range 2m-20.6y)	NR	NR	NR	NR	0 (0) in those with patch repair, no data for suture repair	0 (0) in those with patch repair, no data for suture repair	0 (0) in those with patch repair, no data for suture repair	NR	NR	1 (5.3)	1 (5.3)	NR
Houck 2018	Median 20y (range 6–35y)	NR	NR	0 (0)	NR	1 (5.5) SND	NR	1(5.5)	NR	NR	NR	NR	NR

Iyer 2007	Mean 1.9y	9 (turbulence across pulmonary vein at level of patch mentioned)	1 (2.5)	0 (0)	0 (0)	4 (10) post op junctional rhythm with intermittent sinus escapes , asymptomatic	0 (0)	0 (0)	NR	Reduction of PAH (4)	0 (0)	0 (0)	0 (0) at 1 year
Jemiel ity 1998	Mean 7.8 ± 4y (range 2-16y)	NR	1 (4)	0 (0)	0 (0)	1 (4)	3 (12)	0 (0)	NR	NR	0 (0)	0 (0)	1 (4) at 1 year
Jost 2005	Mean 12y +/- 8.3y	NR	NR	NR	NR	6 (5)	7 (6)	6 (5)	1 (0.9)	NR	1 (0.9)	1 (0.9)	17 (15)

Ling 2016	Mean 4.6y (range 3m - 8y)	0 (0)	NR	NR	0 (0)	0 (0)	NR	0 (0)	NR	1(3.8) post pericardio tomy syndrome, 2(7.8) pericardial effusion, 4(15.4) pleural effusion, 2(7.8) residual shunt, 1(3.8) post op bleeding	0 (0)	0 (0)	NR
Lucia ni 2008	Mean 15± 21y	0 (0)	0 (0)	2 (2.1)	0 (0)	2 (2.1)	11 (11.7) Chron ic AF /flutte r	8 (8.5)	3 (3.2)	89 (95) NYHA class I or II	0 (0)	NR	NR
Misha ly 2007	Mean 12.3± 10.4m (range 6- 45m)	NR	NR	0 (0)	2 (15)	NR	NR	NR	NR	NR	0 (0)	NR	NR

Nassar2012	Mean 4.4y (range 2m - 9.3y)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	NR	NR	0 (0)	0 (0)	NR
Nicholson2000	Mean 4.1y (range 1 - 9y)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (query air embolism , resolved)	NR	0 (0)	0 (0)	0 (0) at 1 year
Panos2002	Mean 12.1 ± 6.1y (range 0.5 - 21y)	NR	NR	0 (0)	NR	NR	NR	NR	NR	NR	0 (0)	0 (0)	0 (0) at 1 year
Rao2019	Mean 1.7y	0 (0)	NR	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	NR	NR	0 (0)	NR	NR

Russel 2002	Media n 8.8y (range 15m – 14.7y)	NR	3 (6.8)	3 (6.8)	1 (2)	Transie nt periope rative AV block in 3 (6.8), of whom 1 (2.3) require d temp pacing; new onset of low atrial rhythm : 3 (8.1), SN dysfun ction at 66 months : 1(2.3)	NR	NR	NR	bleeding in 2(4.5); postperica rdiotomy syndrome with effusion in 4 (9.1), and 1 required drainage	0 (0)	1 (2.3)	NR
------------------------	--	----	---------	---------	-------	---	----	----	----	--	-------	------------	----

Shahriari 2006	Mean 4.3y (range 1 - 13y)	2 (3.7) – 1 Warden repair requiring revision 5 years later, 1 PTFE patch repair not requiring repair	0 (0)	0 (0) in 12 with TTE	1 (1.9)	0 (0)	0 (0)	0 (0)	NR	NR	0 (0)	0 (0)	1 (1.85) acquired pulmonary hypertension
Siddiqui 2013	Mean 6.5± 9.9 m	NR	NR	NR	NR	0 (0)	0 (0)	0 (0)	NR	2 (11) SVT, 1 (0.6) pericardial effusion	0 (0)	NR	NR
Stewart 2007	Weighted overall mean 2.5y	0 (0)	5 (9.3)	NR	NR	17 (31.5) overall junctional/atrial rhythm : 12/22 with two-patch, 5/21 with single patch,	0 (0)	0 (0)	NR	NR	0 (0)	NR	NR

						0/5 with Warde n							
Victor 1995	NR	0 (0)	0 (0)	NR	NR	0 (0)	NR	NR	NR	NR	0 (0)	NR	NR
Vistar ini 2009	Mean 4.3± 2.8y	NR	NR	NR	0 (0)	NR	NR	NR	NR	NR	0 (0)	NR	NR
Yoshi mura 2001	5y	NR	NR	NR	NR	NR	0 (0)	NR	NR	NR	0 (0)	0 (0)	0 (0) at 5 years

NR, not reported; NYHA, New York Heart Association; SVC, superior vena cava; TTE, transthoracic echocardiogram

Table 3. Outcomes

Table 3. Outcomes								
Outcome	Studies	Events	Total number of patients	Weighted mean follow-up period	Estimate, %	95% CI	Tau2	I2%
Mortality, in-hospital	39	3	1242	7 days	NA	NA	NA	NA
Mortality, 30 days	21	4	720	30 days	NA	NA	NA	NA
Atrial fibrillation	19	23	692	6.5 years	2%	1% to 3%	<0.01	21%
Sinus node dysfunction	21	66	1013	6.4 years	4%	2% to 6%	<0.01	74%
Pacemaker insertion	15	16	717	8.6 years	2%	1% to 2%	<0.01	0%
Cerebrovascular accident	5	6	296	12.3 years	1%	0% to 3%	<0.01	0%
Reoperation	20	11	807	9.5 years	1%	0% to 2%	<0.01	0%

Residual septal defect	22	10	747	9.3 years	2%	2% to 2%	<0.01	99%
Superior vena cava obstruction	18	14	795	8.9 years	1%	1% to 1%	<0.01	100%
Reimplanted pulmonary vein obstruction	18	11	784	8.7 years	2%	2% to 2%	<0.01	100%